ASND
Ascendis Pharma A/S
There isn't enough reported data to score ASND yet.
ASND Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Under pressure | |
| Strong |
ASND's profitability and balance sheet are currently healthy, but its cash flow is under pressure. There isn't enough data to rate its revenue.
ASND PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $267 | — |
| Cheap | 22x | $313 | +17% |
| Fair | 27x | $388 | +45% |
| Expensive | 29x | $428 | +60% |
Historical ranges are pointers, not guarantees.
ASND's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
ASND Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ASND, with profitability improving. However, they disagree widely on these estimates.
ASND Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $14.54 | +$18.78 |
| Q4 2025 | -$4.18 | +$3.07 |
| Q3 2025 | -$4.24 | +$4.05 |
| Q2 2025 | -$5.04 | +$4.54 |
| Q1 2025 | -$6.45 | +$3.41 |
| Q4 2024 | -$7.25 | +$2.25 |
| Q3 2024 | -$8.29 | +$3.61 |
| Q2 2024 | -$9.58 | +$2.49 |
ASND has returned to profit: it earned $14.54 per share over the past year, after losing money the year before.
ASND Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +347% |
| Q4 2025 | $274.9M | +42% |
| Q3 2025 | $237.3M | +269% |
| Q2 2025 | $175.6M | +339% |
| Q1 2025 | $112.1M | +5.3% |
| Q4 2024 | $193.2M | +26% |
| Q3 2024 | $64.2M | +20% |
| Q2 2024 | $40M | -24% |
ASND's revenue has grown year over year for seven quarters in a row: $1.1B last quarter, up 847% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 39% | +142 points |
| Q4 2025 | 4% | +3.8 points |
| Q3 2025 | 5.2% | +172 points |
| Q2 2025 | -34% | +337 points |
| Q1 2025 | -103% | -52 points |
| Q4 2024 | 0.2% | +27 points |
| Q3 2024 | -167% | +113 points |
| Q2 2024 | -370% | -73 points |
ASND's operating margin was 39% last quarter, up 142 points from the same quarter a year ago, near the top of its range since 2019.
ASND Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$62.9M | +$76.8M |
| Q2 2024 | -$68.5M | +$102.1M |
| Q1 2024 | -$113.1M | +$51.5M |
| Q4 2023 | -$47.1M | +$114.5M |
| Q3 2023 | -$139.6M | -$26.3M |
| Q2 2023 | -$170.6M | -$28.3M |
| Q1 2023 | -$164.6M | -$15M |
| Q4 2022 | -$161.6M | -$19.3M |
ASND has burned cash in almost every quarter: −$292M over the past year, against −$636M the year before.
ASND Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +6.2M shares |
| 1 year | +11% | +6.8M shares |
| 3 years | +19% | +10.7M shares |
| 5 years | +24% | +13M shares |
| Available history | +42% | +19.6M shares |
ASND has 67M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $173.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $19.3M |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $2,222 |
ASND Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
ASND has more cash than debt.
ASND Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 73.4 | Neutral |
ASND's weekly RSI is 59 (neutral) and its Stochastic is 73 (neutral).
ASND PE vs Healthcare Sector
| Metric | ASND | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 4 | 29 | 25 pts below |
ASND is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ASND Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $240.8 | 11% above |
| 20 week MA | $250.3 | 6.7% above |
| 50 week MA | $235.2 | 14% above |
| 100 week MA | $202.9 | 32% above |
| 200 week MA | $160.1 | 67% above |
ASND is in an uptrend: it's above all five of its weekly moving averages, and 67% above its 200-week average.
ASND Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $135.1 | $170.9 | +27% |
| 2021 | $170.9 | $139.3 | -18% |
| 2022 | $139.3 | $119.1 | -15% |
| 2023 | $119.1 | $126.0 | +5.8% |
| 2024 | $126.0 | $137.5 | +9.2% |
| 2025 | $137.5 | $209.0 | +52% |
| 2026 YTD | $209.0 | $267.1 | +28% |
ASND has finished higher in four of the last six years. It's up 28% so far in 2026.